臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :2822924
	造访人次 : 30060319 在线人数 : 1124 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"enatsu s"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 1-10 / 12 (共2页)
1 2 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2021-05-02T03:49:13Z	Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY	Nishio M.;Seto T.;Reck M.;Garon E.B.;Chiu C.-H.;Yoh K.;Imamura F.;Park K.;Jin-Yuan Shih;Visseren-Grul C.;Frimodt-Moller B.;Zimmermann A.;Homma G.;Enatsu S.;Nakagawa K.;Relay Study Investigators; Nishio M.; Seto T.; Reck M.; Garon E.B.; Chiu C.-H.; Yoh K.; Imamura F.; Park K.; JIN-YUAN SHIH; Visseren-Grul C.; Frimodt-Moller B.; Zimmermann A.; Homma G.; Enatsu S.; Nakagawa K.; RELAY Study Investigators
臺大學術典藏	2021-04-23T05:56:33Z	A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis	Chih-Hsin Yang;Cheng Y.;Murakami H.;Yang P.-C.;He J.;Nakagawa K.;Kang J.H.;Kim J.-H.;Hozak R.R.;Nguyen T.S.;Zhang W.L.;Enatsu S.;Puri T.;Orlando M.; CHIH-HSIN YANG; Cheng Y.; Murakami H.; Yang P.-C.; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M.
臺大學術典藏	2020-12-02T02:33:19Z	Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations	Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Wang X.; Enatsu S.; Puri T.; Orlando M.; Yang J.C.-H.; Cheng Y.; PAN-CHYR YANG et al.
臺大學術典藏	2020-12-02T02:33:06Z	A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis	Yang J.C.-H.; PAN-CHYR YANG et al.; Yang J.C.-H.; Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M.
臺大學術典藏	2020-08-13T06:33:24Z	The relevance of docetaxel-related febrile neutropenia to patient-reported symptoms and the quality of life in Japanese, East Asian (Korean, Taiwanese), and Non-east asian patients based on post-hoc analyses of two randomized clinical trials of docetaxel with and without anti-angiogenic agent in advanced non-small cell lung cancer after progression on platinum-based chemotherapy	Inoue A.; Omori Y.;Enatsu S.;Brnabic A.J.M.;Rajan N.;Jin-Yuan Shih;Kim J.-H.;Park K.;Inoue A.; Omori Y.; Enatsu S.; Brnabic A.J.M.; Rajan N.; JIN-YUAN SHIH; Kim J.-H.; Park K.
臺大學術典藏	2020-08-13T06:33:24Z	The relevance of docetaxel-related febrile neutropenia to patient-reported symptoms and the quality of life in Japanese, East Asian (Korean, Taiwanese), and Non-east asian patients based on post-hoc analyses of two randomized clinical trials of docetaxel with and without anti-angiogenic agent in advanced non-small cell lung cancer after progression on platinum-based chemotherapy	Inoue A.; Omori Y.;Enatsu S.;Brnabic A.J.M.;Rajan N.;Jin-Yuan Shih;Kim J.-H.;Park K.;Inoue A.; Omori Y.; Enatsu S.; Brnabic A.J.M.; Rajan N.; JIN-YUAN SHIH; Kim J.-H.; Park K.
臺大學術典藏	2020-05-26T09:26:55Z	Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT	Orlando M.;Cheng R;Enatsu S;Barraclough H;Tamura T;Nakagawa K;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M.
臺大學術典藏	2020-05-26T09:26:55Z	Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT	Orlando M.;Cheng R;Enatsu S;Barraclough H;Tamura T;Nakagawa K;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M.
臺大學術典藏	2020-05-26T09:26:44Z	Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations	Chih-Hsin Yang;Orlando M;Puri T;Enatsu S;Wang X;Kim J.-H;Kang J.H;Nakagawa K;He J;Yang P.-C;Murakami H;Cheng Y; Cheng Y; Murakami H; Yang P.-C; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:44Z	Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations	Chih-Hsin Yang;Orlando M;Puri T;Enatsu S;Wang X;Kim J.-H;Kang J.H;Nakagawa K;He J;Yang P.-C;Murakami H;Cheng Y; Cheng Y; Murakami H; Yang P.-C; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG

显示项目 1-10 / 12 (共2页)
1 2 > >>
每页显示[10|25|50]项目